Cargando…
Allergen immunotherapy for house dust mite-induced rhinitis: prescriptive criteria
Allergic rhinitis (AR) is a very common disease. In most cases, therapy is based on symptomatic drugs, while allergen immunotherapy (AIT), which is the only one to act on the cause of the disease, is reserved for patients with a greater burden of disease. In particular, the possible evolution toward...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Mattioli 1885
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8182604/ https://www.ncbi.nlm.nih.gov/pubmed/33988150 http://dx.doi.org/10.23750/abm.v92i2.11011 |
_version_ | 1783704243297845248 |
---|---|
author | Incorvaia, Cristoforo Ridolo, Erminia Ciprandi, Giorgio |
author_facet | Incorvaia, Cristoforo Ridolo, Erminia Ciprandi, Giorgio |
author_sort | Incorvaia, Cristoforo |
collection | PubMed |
description | Allergic rhinitis (AR) is a very common disease. In most cases, therapy is based on symptomatic drugs, while allergen immunotherapy (AIT), which is the only one to act on the cause of the disease, is reserved for patients with a greater burden of disease. In particular, the possible evolution towards asthma substantiates the use of AIT, but requires the availability of diagnostic indices related to the risk of developing asthma. We analyzed the available literature on risk factors for onset of asthma in patients with AR, including bronchial hyperresponsiveness, uncovering by respiratory function tests of airway impairment, measurement of fractioned exhaled nitric oxide, given IgE sensitization pattern, and respiratory infections detected by nasal mucus samples or by particular microbiomes. Most of these risk predictors have been investigated too little or do not have consistent results, while various studies have confirmed that early bronchial impairment in AR patients, particularly concerning small airways, should be considered as prescriptive criteria for AIT. (www.actabiomedica.it) |
format | Online Article Text |
id | pubmed-8182604 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Mattioli 1885 |
record_format | MEDLINE/PubMed |
spelling | pubmed-81826042021-06-16 Allergen immunotherapy for house dust mite-induced rhinitis: prescriptive criteria Incorvaia, Cristoforo Ridolo, Erminia Ciprandi, Giorgio Acta Biomed Original Article Allergic rhinitis (AR) is a very common disease. In most cases, therapy is based on symptomatic drugs, while allergen immunotherapy (AIT), which is the only one to act on the cause of the disease, is reserved for patients with a greater burden of disease. In particular, the possible evolution towards asthma substantiates the use of AIT, but requires the availability of diagnostic indices related to the risk of developing asthma. We analyzed the available literature on risk factors for onset of asthma in patients with AR, including bronchial hyperresponsiveness, uncovering by respiratory function tests of airway impairment, measurement of fractioned exhaled nitric oxide, given IgE sensitization pattern, and respiratory infections detected by nasal mucus samples or by particular microbiomes. Most of these risk predictors have been investigated too little or do not have consistent results, while various studies have confirmed that early bronchial impairment in AR patients, particularly concerning small airways, should be considered as prescriptive criteria for AIT. (www.actabiomedica.it) Mattioli 1885 2021 2021-05-12 /pmc/articles/PMC8182604/ /pubmed/33988150 http://dx.doi.org/10.23750/abm.v92i2.11011 Text en Copyright: © 2020 ACTA BIO MEDICA SOCIETY OF MEDICINE AND NATURAL SCIENCES OF PARMA https://creativecommons.org/licenses/by-nc-sa/4.0/This work is licensed under a Creative Commons Attribution 4.0 International License |
spellingShingle | Original Article Incorvaia, Cristoforo Ridolo, Erminia Ciprandi, Giorgio Allergen immunotherapy for house dust mite-induced rhinitis: prescriptive criteria |
title | Allergen immunotherapy for house dust mite-induced rhinitis: prescriptive criteria |
title_full | Allergen immunotherapy for house dust mite-induced rhinitis: prescriptive criteria |
title_fullStr | Allergen immunotherapy for house dust mite-induced rhinitis: prescriptive criteria |
title_full_unstemmed | Allergen immunotherapy for house dust mite-induced rhinitis: prescriptive criteria |
title_short | Allergen immunotherapy for house dust mite-induced rhinitis: prescriptive criteria |
title_sort | allergen immunotherapy for house dust mite-induced rhinitis: prescriptive criteria |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8182604/ https://www.ncbi.nlm.nih.gov/pubmed/33988150 http://dx.doi.org/10.23750/abm.v92i2.11011 |
work_keys_str_mv | AT incorvaiacristoforo allergenimmunotherapyforhousedustmiteinducedrhinitisprescriptivecriteria AT ridoloerminia allergenimmunotherapyforhousedustmiteinducedrhinitisprescriptivecriteria AT ciprandigiorgio allergenimmunotherapyforhousedustmiteinducedrhinitisprescriptivecriteria |